More drug trials end early hiding potential problemsBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7525.1103-a (Published 10 November 2005) Cite this as: BMJ 2005;331:1103
- Michael Day
A growing number of trials sponsored by the drug industry are halted early on the grounds that apparent treatment benefits have emerged rapidly. The warning comes from Canadian researchers whose review of 143 randomised controlled trials has found a “frequent failure to report relevant information” and “implausibly large treatment effects” (JAMA 2005;294:2228-30).
The proportion of randomised trials halted early has doubled in the past 10 years, from 0.5% in 1990-4 to 1.2% in 2000-4. And the scientific validity of the data they provide is not proved, say the researchers from McMaster University, Ontario, Canada.
Dr Victor Montori, the lead …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial